192 related articles for article (PubMed ID: 37332966)
1. Long-term efficacy of sodium-glucose cotransporter 2 inhibitor therapy in preventing atrial fibrillation recurrence after catheter ablation in type 2 diabetes mellitus patients.
Liu HT; Wo HT; Chang PC; Lee HL; Wen MS; Chou CC
Heliyon; 2023 Jun; 9(6):e16835. PubMed ID: 37332966
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of Sodium-Glucose Cotransporter 2 Inhibitors on Outcomes After Catheter Ablation for Atrial Fibrillation.
Kishima H; Mine T; Fukuhara E; Kitagaki R; Asakura M; Ishihara M
JACC Clin Electrophysiol; 2022 Nov; 8(11):1393-1404. PubMed ID: 36424008
[TBL] [Abstract][Full Text] [Related]
3. Impact of Sodium-Glucose Cotransporter 2 Inhibitor on Recurrence After Catheter Ablation for Atrial Fibrillation in Patients With Diabetes: A Propensity-Score Matching Study and Meta-Analysis.
Zhao Z; Jiang C; He L; Zheng S; Wang Y; Gao M; Lai Y; Zhang J; Li M; Dai W; Zuo S; Guo X; Li S; Jiang C; Liu N; Tang R; Long D; Du X; Sang C; Dong J; Ma C
J Am Heart Assoc; 2023 Dec; 12(24):e031269. PubMed ID: 38084708
[TBL] [Abstract][Full Text] [Related]
4. The impact of weight loss related to risk of new-onset atrial fibrillation in patients with type 2 diabetes mellitus treated with sodium-glucose cotransporter 2 inhibitor.
Chan YH; Chen SW; Chao TF; Kao YW; Huang CY; Chu PH
Cardiovasc Diabetol; 2021 Apr; 20(1):93. PubMed ID: 33941171
[TBL] [Abstract][Full Text] [Related]
5. The risk of new-onset atrial fibrillation in patients with type 2 diabetes mellitus treated with sodium glucose cotransporter 2 inhibitors versus dipeptidyl peptidase-4 inhibitors.
Ling AW; Chan CC; Chen SW; Kao YW; Huang CY; Chan YH; Chu PH
Cardiovasc Diabetol; 2020 Nov; 19(1):188. PubMed ID: 33158436
[TBL] [Abstract][Full Text] [Related]
6. Sodium glucose cotransporter-2 inhibitor was associated with an improvement in left ventricular systolic function in patients with type 2 diabetes mellitus with impaired left ventricular systolic function.
Chan YH; Hsu TJ; Wang CL; Kao YW; Huang CY; Chu PH
ESC Heart Fail; 2020 Oct; 7(5):2784-2796. PubMed ID: 32627380
[TBL] [Abstract][Full Text] [Related]
7. Sodium-Glucose Cotransporter-2 Inhibitor Prevents Stroke in Patients With Diabetes and Atrial Fibrillation.
Chang SN; Chen JJ; Huang PS; Wu CK; Wang YC; Hwang JJ; Tsai CT
J Am Heart Assoc; 2023 May; 12(10):e027764. PubMed ID: 37183872
[TBL] [Abstract][Full Text] [Related]
8. The risk of incident atrial fibrillation in patients with type 2 diabetes treated with sodium glucose cotransporter-2 inhibitors, glucagon-like peptide-1 receptor agonists, and dipeptidyl peptidase-4 inhibitors: a nationwide cohort study.
Chan YH; Chao TF; Chen SW; Lee HF; Li PR; Chen WM; Yeh YH; Kuo CT; See LC; Lip GYH
Cardiovasc Diabetol; 2022 Jun; 21(1):118. PubMed ID: 35765074
[TBL] [Abstract][Full Text] [Related]
9. Long-term follow-up after catheter ablation of paroxysmal atrial fibrillation: the incidence of recurrence and progression of atrial fibrillation.
Takigawa M; Takahashi A; Kuwahara T; Okubo K; Takahashi Y; Watari Y; Takagi K; Fujino T; Kimura S; Hikita H; Tomita M; Hirao K; Isobe M
Circ Arrhythm Electrophysiol; 2014 Apr; 7(2):267-73. PubMed ID: 24610740
[TBL] [Abstract][Full Text] [Related]
10. Risks of stroke, its subtypes and atrial fibrillation associated with glucagon-like peptide 1 receptor agonists versus sodium-glucose cotransporter 2 inhibitors: a real-world population-based cohort study in Hong Kong.
Lui DTW; Tang EHM; Wu T; Au ICH; Lee CH; Woo YC; Tan KCB; Wong CKH
Cardiovasc Diabetol; 2023 Feb; 22(1):40. PubMed ID: 36829226
[TBL] [Abstract][Full Text] [Related]
11. QTc interval predicts outcome of catheter ablation in paroxysmal atrial fibrillation patients with type 2 diabetes mellitus.
Ma N; Wu XY; Ma CS; Liu N; Bai R; Du X; Ruan YF; Dong JZ
J Huazhong Univ Sci Technolog Med Sci; 2016 Oct; 36(5):646-652. PubMed ID: 27752887
[TBL] [Abstract][Full Text] [Related]
12. Efficacy, safety, and outcomes of catheter ablation of atrial fibrillation in patients with heart failure with preserved ejection fraction.
Machino-Ohtsuka T; Seo Y; Ishizu T; Sugano A; Atsumi A; Yamamoto M; Kawamura R; Machino T; Kuroki K; Yamasaki H; Igarashi M; Sekiguchi Y; Aonuma K
J Am Coll Cardiol; 2013 Nov; 62(20):1857-65. PubMed ID: 23916940
[TBL] [Abstract][Full Text] [Related]
13. Effect of metformin on outcomes of catheter ablation for atrial fibrillation.
Deshmukh A; Ghannam M; Liang J; Saeed M; Cunnane R; Ghanbari H; Latchamsetty R; Crawford T; Batul SA; Chung E; Bogun F; Jongnarangsin K; Pelosi F; Chugh A; Morady F; Oral E; Oral H
J Cardiovasc Electrophysiol; 2021 May; 32(5):1232-1239. PubMed ID: 33600005
[TBL] [Abstract][Full Text] [Related]
14. Association of pretreatment with angiotensin-converting enzyme inhibitors with improvement in ablation outcome in atrial fibrillation patients with low left ventricular ejection fraction.
Mohanty S; Mohanty P; Trivedi C; Gianni C; Bai R; Burkhardt JD; Gallinghouse JG; Horton R; Sanchez JE; Hranitzky PM; Al-Ahmad A; Bailey S; Di Biase L; Natale A
Heart Rhythm; 2015 Sep; 12(9):1963-71. PubMed ID: 26051531
[TBL] [Abstract][Full Text] [Related]
15. Sex-related risks of recurrence of atrial fibrillation after ablation: Insights from the Guangzhou Atrial Fibrillation Ablation Registry.
Deng H; Shantsila A; Guo P; Potpara TS; Zhan X; Fang X; Liao H; Liu Y; Wei W; Fu L; Xue Y; Wu S; Lip GYH
Arch Cardiovasc Dis; 2019 Mar; 112(3):171-179. PubMed ID: 30683618
[TBL] [Abstract][Full Text] [Related]
16. Impact of nocturnal hypoxemia on the recurrence of atrial tachyarrhythmia after catheter ablation of atrial fibrillation.
Suzuki K; Miyamoto K; Wakamiya A; Ueda N; Nakajima K; Kamakura T; Wada M; Yamagata K; Ishibashi K; Inoue Y; Noda T; Nagase S; Aiba T; Yambe T; Kusano K
Heart Vessels; 2022 May; 37(5):794-801. PubMed ID: 34677657
[TBL] [Abstract][Full Text] [Related]
17. Beneficial effects of sodium glucose cotransporter 2 inhibitors on left ventricular mass in patients with diabetes mellitus.
Kosugi D; Inaba H; Kaido Y; Ito S; Hirobata T; Toyofuku M; Matsuoka T; Inoue G
J Diabetes; 2021 Nov; 13(11):847-856. PubMed ID: 34231959
[TBL] [Abstract][Full Text] [Related]
18. The predictive value of echocardiographic parameters associated with left ventricular diastolic dysfunction on short- and long-term outcomes of catheter ablation of atrial fibrillation.
Kosiuk J; Breithardt OA; Bode K; Kornej J; Arya A; Piorkowski C; Gaspar T; Sommer P; Husser D; Hindricks G; Bollmann A
Europace; 2014 Aug; 16(8):1168-74. PubMed ID: 24569573
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of catheter ablation in nonparoxysmal atrial fibrillation patients with severe enlarged left atrium and its impact on left atrial structural remodeling.
Pump A; Di Biase L; Price J; Mohanty P; Bai R; Santangeli P; Mohanty S; Trivedi C; Yan RX; Horton R; Sanchez JE; Zagrodzky J; Bailey S; Gallinghouse GJ; Burkhardt JD; Natale A
J Cardiovasc Electrophysiol; 2013 Nov; 24(11):1224-31. PubMed ID: 24020717
[TBL] [Abstract][Full Text] [Related]
20. Impact of the initial decline in estimated glomerular filtration rate on the risk of new-onset atrial fibrillation and adverse cardiovascular and renal events in patients with type 2 diabetes treated with sodium-glucose co-transporter-2 inhibitors.
Chan YH; Chen SW; Chao TF; Kao YW; Huang CY; Chu PH
Diabetes Obes Metab; 2021 Sep; 23(9):2077-2089. PubMed ID: 34047459
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
